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Since the WHO “Guidelines on Evaluation of Similar
Biotherapeutic Products (SBPs)” was published in April
2010[1], twenty two Countries and regions including EU
and FDA have established their guidelines or guideline
drafts on evaluation of biosimilar.
In terms of the technical features, WHO guidelines are
consistent with that of EU[2-4], head-to-head comparison
exercise between SBP and reference biotherapeutic pro-
duct (RBP) are required. In the prerequisite of quality
similarity, the unnecessary or repeated non-clinical and/or
clinical data might be reduced. Furthermore, extrapolation
to other indications of the RBP may be possible. As for the
FDA draft, requirements of interchangeability and substi-
tution of SBP with RBP were introduced [5,6]. Guidelines
of other developing countries generally used the WHO
guidelines and the FDA guidance draft as blueprints to set
up the technical requirements. These regulations and
guidelines have far-reaching significance for each country’s
biotechnology industry development and the availability
and affordability of public medicine use.
Up to now, there are not yet specified regulations for
SBPs in China. Based on “The Provisions for Drug Regis-
tration (SFDA Order 28)” [7], Part I “Biological Products
for Therapeutic Use” of the appendix 3 includes fifteen
categories, three of them (7, 10 and 15) are related to
SBPs. With respect to the technical requirements, there
are no essential differences between China and WHO
guidelines. However, our current regulations pay more
attention to the requirements for the new drug approval.
Consequently, some candidate SBPs products which might
be suitable for abbreviated licensure pathway still need to
experience the complete non-clinical and clinical studies.
In addition, extrapolating to other indications is not
allowed in our current regulations.
Among the research projects of the “Twelfth Five-Year
Plan” significant new drugs creation special, me too bio-
threapeutics are still the major part of the projects of bio-
technology medicines. Therefore, accelerating the process
of establishing our SBPs guidelines has great benefit for
achieving the goal of ensuring the availability and afford-
ability of public medicine and improving the develop-
ment of our country’s biotechnology industry. Recently,
our department has initiated the process of surveying the
need to draft a specified SBP guideline. As some sugges-
tions, due to very hard to obtain and very high costing of
RBP would surely increase the difficulties of developing
and evaluation of SBPs, how to define the requirement of
RBP should be elaborately considered during the process
of establishing our guidelines. Besides, special attention
should be focused on how to perform the comparability
exercise with RBP in the non-clinical and/or clinical
study during the development of SBPs of therapeutic
monoclonal antibodies. We believe that a SBPs guideline
which considering both the actual situation of develop-
ment of biomedicine in China and the general WHO fra-
mework would be established in the near future.
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